DIPG实验治疗神经评估量表PONScore的开发
本研究开发了用于弥漫性内生型脑桥胶质瘤(DIPG)实验治疗期间神经功能监测的PONScore量表,由非专科护士每小时评估。在6例8-11岁儿童的30次输注中,护士与专科医师评分组内相关系数0.98(95%CI 0.97-0.99,P<0.001),Spearman相关系数0.985(P<0.001);另55次输注中PONScore从3.3升至5.7(P<0.001),反映神经症状累积。
要点
- PONScore可由非专科护士操作,评估DIPG患儿急性神经功能变化
- 护士与专科医师评分一致性高,组内相关系数0.98
- 输注期间PONScore从3.3升至5.7,提示症状累积
核心结论
- PONScore是一种可由非专科人员使用的神经量表,能描述DIPG患儿实验治疗中的急性神经变化。
- 该量表尚需作为临床试验的一部分进行前瞻性验证。
研究设计与样本
- 开发PONScore量表,改编自已验证的儿童神经症状评估量表。
- 培训儿科重症监护护士使用量表,评估接受清醒脑桥输注化疗的DIPG患儿。
- 在6例8-11岁儿童的30次输注中比较护士与专科医师评分的一致性和相关性。
- 在8例3-11岁儿童的55次输注中描述PONScore随输注体积的变化。
主要发现
- 护士与专科医师评分的组内相关系数为0.98(95%CI 0.97-0.99,P<0.001)。
- 护士与专科医师评分的Spearman相关系数为0.985(P<0.001)。
- 输注期间PONScore从3.3升至5.7(P<0.001),反映神经体征和症状累积。
关键数值与推荐
- PONScore对头痛、眼肌麻痹、面舌无力、构音障碍、感觉异常、肢体无力和辨距不良计分,分数越高残疾越重。
- 清醒脑桥输注期间每小时实施PONScore评估。
临床怎么用
- 非专科护士可每小时使用PONScore监测DIPG实验治疗中的急性神经变化。
- 评分升高提示输注期间神经症状累积,需关注。
局限性
- 样本量小,仅纳入6例和8例儿童。
- 尚未进行前瞻性临床试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Monitoring neurological side-effects in experimental therapy for diffuse intrinsic pontine glioma (DIPG) can be challenging. We aimed to develop a neurological scale that could be used by non-specialists to quantify neurological changes during experimental treatment of DIPG. METHODS: We developed the Pontine Observational Neurological Score (PONScore) to measure signs and symptoms of DIPG by adapting validated assessment scales of neurological signs and symptoms in children. We developed a prototype score, taught it to paediatric intensive care nursing staff, who used the Score to assess children receiving awake pontine infusion of chemotherapy for treatment of DIPG. We used their feedback to develop the PONScore. Points are allocated for headache, ophthalmoplegia, facial and tongue weakness, dysarthria, paraesthesia, limb weakness and dysmetria with increasing scores reflecting increasing disability. The PONScore was administered every hour during awake pontine infusion. Correlation and agreement calculations between nursing staff, as non-specialists, and a specialist rater were performed in 30 infusions in 6 children (aged 8-11). Changes in PONScore versus volume of infusion are described in a further 55 infusions in 8 children (aged 3-11). RESULTS: The PONScore demonstrated excellent intra-rater reliability with an intra-class co-efficient of 0.98 (95% CI 0.97-0.99; p-value < 0.001) between a specialist and non-specialist raters with strong correlation between scores and a Spearman correlation coefficient of 0.985 (p < 0.001). PONScores increased from 3.3 to 5.7 (p-value < 0.001) during infusion reflecting accumulation of neurological signs and symptoms during infusion. CONCLUSIONS: We describe a novel neurological scale that can be used by non-specialists to describe acute neurological changes in children receiving experimental therapy for DIPG. Prospective validation as part of a clinical trial is required.
引用
- Hollingworth MA, Zacharoulis S. Development of a clinical scale for assessment of patients with diffuse intrinsic pontine glioma (DIPG) receiving experimental therapy: the PONScore. J Neurooncol. 2020. PMID: 32902768. doi:10.1007/s11060-020-03594-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。